Elevated Liver Enzymes along with Comorbidity Is a High Risk Factor for COVID-19 Mortality: A South Indian Study on 1,512 Patients
Liver enzyme abnormalities in coronavirus 2019 (COVID-19) are being addressed in the literature. The predictive risk of elevated liver enzymes has not been established for COVID-19 mortality. In this study, we hypothesized that elevated liver enzymes at admission can predict the outcome of COVID-19...
Saved in:
Published in | Journal of clinical and translational hepatology Vol. 10; no. 1; pp. 120 - 127 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
China
XIA & HE Publishing Inc
28.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Liver enzyme abnormalities in coronavirus 2019 (COVID-19) are being addressed in the literature. The predictive risk of elevated liver enzymes has not been established for COVID-19 mortality. In this study, we hypothesized that elevated liver enzymes at admission can predict the outcome of COVID-19 disease with other known indicators, such as comorbidities.
This retrospective study included all the consecutive hospitalized patients with confirmed COVID-19 disease from March 4
to May 31
, 2020. The study was conducted in Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India. We assessed demography, clinical variables, COVID-19 severity, laboratory parameters, and outcome.
We included 1,512 patients, and median age was 47 years (interquartile range: 34-60) with 36.9% being female. Liver enzyme level (aspartate aminotransferase and/or alanine aminotransferase) was elevated in 450/1,512 (29.76%) patients. Comorbidity was present in 713/1,512 (47.16%) patients. Patients with liver enzymes' elevation and presence of comorbidity were older, more frequently hospitalized in ICU and had more severe symptoms of COVID-19 at the time of admission. Presence of liver enzymes' elevation with comorbidity was a high risk factor for death (OR: 5.314, 95% CI: 2.278-12.393), as compared to patients with presence of comorbidity (OR: 4.096, 95% CI: 1.833-9.157).
Comorbidity combined with liver enzymes' elevation at presentation independently increased the risk of death in COVID-19 by at least 5-fold. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 None to declare. Overall study supervision (NK), conception of the study design, data analysis, drafting of the article, and statistical analysis (KR), assistance in drafting of the article (PB), and assistance in acquisition of data (AR, PP, MR). The authors have no conflict of interests related to this publication. |
ISSN: | 2225-0719 2310-8819 |
DOI: | 10.14218/JCTH.2020.00100 |